NDRG2 correlated with favorable recurrence-free survival inhibits metastasis of mouse breast cancer cells via attenuation of active TGF-β production

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1882-1888

  Oh, Sang Seok ^a   Kim, Donghyeok ^a   Kim, Dong Hee ^b   Chang, Hong Hee ^a   Sohn, Kyung Cheol ^c   Kim, Kyo Hyun ^d   Jung, Sung Hoo ^e   Lee, Byoung Kil ^e   Kim, Joo Heon ^d   Kim, Kwang Dong ^a  

^a Gyeongsang National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Chungnam National University   (South Korea)

^d Eulji University School of Medicine   (South Korea)

^e Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MYC PROTEIN; N MYC DOWNSTREAM REGULATED GENE 2; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELL GROWTH; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEINS; RECURRENCE; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

EID: 84867303575     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs211     Document Type: Article

References (41)

1. Qu, X. et al. (2002) Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell. Biochem., 229, 35-44.
2. Furuta, H. et al. (2010) NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma. Biochem. Biophys. Res. Commun., 391, 1785-1791.
3. Kim, A. et al. (2009) Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis, 30, 927-936.
4. Kim, Y.J. et al. (2009) NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int. J. Cancer, 124, 7-15.
5. Piepoli, A. et al. (2009) Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med. Genomics, 2, 11.
6. Tepel, M. et al. (2008) Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int. J. Cancer, 123, 2080-2086.
7. Liu, N. et al. (2007) Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem. Biophys. Res. Commun., 358, 164-169.
8. Lusis, E.A. et al. (2005) Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res., 65, 7121-7126.
9. Deng, Y. et al. (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int. J. Cancer, 106, 342-347.
10. Choi, S.C. et al. (2003) Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells. FEBS Lett., 553, 413-418.
11. Liu, N. et al. (2008) N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res., 36, 5335-5349.
12. Lee, D.C. et al. (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res., 68, 4210-4220.
13. Kim, Y.J. et al. (2009) NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis, 30, 598-605.
14. Eccles, S.A. et al. (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet, 369, 1742-1757.
15. Nicolini, A. et al. (2006) Metastatic breast cancer: an updating. Biomed. Pharmacother., 60, 548-556.
16. Steeg, P.S. (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med., 12, 895-904.
17. Robbins, P. et al. (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Hum. Pathol., 26, 873-879.
18. Elston, C.W. et al. (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 41(3A), 154-161.
19. Jemal, A. et al. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
20. Falkson, G. et al. (1990) Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer, 66, 1621-1629.
21. Greenberg, P.A. et al. (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol., 14, 2197-2205.
22. Giordano, S.H. et al. (2004) Is breast cancer survival improving? Cancer, 100, 44-52.
23. Chia, S.K. et al. (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer, 110, 973-979.
24. Kamangar, F. et al. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol., 24, 2137-2150.
25. Lorentzen, A. et al. (2011) Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer. BMC Cancer, 11, 14.
26. Zheng, J. et al. (2011) NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer, 11, 251:1-251:9.
27. Zheng, J. et al. (2010) NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells. Asian Pac. J. Cancer Prev., 11, 1817-1821.
28. Shon, S.K. et al. (2009) Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem. Biophys. Res. Commun., 385, 198-203.
29. Chu, D. et al. (2011) Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol. Cancer Ther., 10, 47-56.
30. Mordalska, A. et al. (2010) Evaluation of NDRG2 gene expression in primary papillary thyroid carcinoma and in metastases of this neoplasm to regional lymph nodes. Thyroid Res., 3, 6.
31. Skiriute, D. et al. (2011) Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas. J. Neurooncol., 102, 89-94.
32. Aslakson, C.J. et al. (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res., 52, 1399-1405.
33. Tao, K. et al. (2008) Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer, 8, 228.
34. Jakowlew, S.B. (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev., 25, 435-457.
35. Padua, D. et al. (2008) TGF beta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell, 133, 66-77.
36. Siegel, P.M. et al. (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer, 3, 807-821.
37. Munger, J.S. et al. (1999) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell, 96, 319-328.
38. Yokosaki, Y. et al. (1996) Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. J. Biol. Chem., 271, 24144-24150.
39. Van Aarsen, L.A. et al. (2008) Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res., 68, 561-570.
40. Ramos, D.M. et al. (2009) The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res., 29, 125-130.
41. Marsh, D. et al. (2008) alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res., 68, 3295-3303.